Date: 2016-11-23
Type of information: Development agreement
Compound: IMP321
Company: Prima Biomed (Australia) WuXi Biologics (China)
Therapeutic area: Cancer - Oncology
Type agreement: development manufacturing bioproduction
Action mechanism: immunotherapy product/fusion protein. IMP321 is an antigen presenting cell (APC) activator. LAG-3, or Lymphocyte Activation Gene 3, is an immune checkpoint receptor able to stimulate and in other cases inhibit an immune response, through involvement in a number of immune pathways. IMP321 is a soluble LAG-3Ig fusion protein which works by binding to MHC class II molecules on antigen-presenting cells (APCs) such as dendritic cells to activate them. The APCs are important for showing cancer antigens to T cells and activating them to destroy cancer cells. IMP321 is a firstin-class APC activator. The product has been developed by the french company Immutep which Prima Biomed acquired in December 2014.
Disease:
Details: * On November 23, 2016, Prima BioMed and WuXi Biologics announced that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership. Under the partnership, WuXi Biologics will be the exclusive clinical and commercial manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of mainland China, Macau, Taiwan and Hong Kong where rights are retained by Prima’s development partner in China, Eddingpharm. WuXi Biologics will also be Prima’s preferred partner to manufacture potential new products.
Financial terms:
Latest news:
